Welcome to Dilafor

Dilafor develops pharmaceutical products from heparin derivatives with low anticoagulant activity.
The company has a balanced product portfolio representing some highly promising ideas and innovations. Each of our projects addresses an important and unfulfilled medical need.

All our drug development projects are based on the use of Low Anticoagulant Heparin (LAH). Although standard heparin has numerous biological functions, its potential development as a treatment for indications other than those currently approved is limited by its anticoagulative properties. Dilafor has produced several forms of LAH.
Two products are presently in development; tafoxiparin, for the prevention and normalization of protracted labor, has recently completed a Phase II Proof of Concept clinical trial in Phase II. Promising results were found in the trial, where 263 women were included. Statistically significant less women were found in the group that was treated with tafoxiparin, in comparison with placebo. A Phase I "First In Man" trial of sevuparin, for the treatment of severe malaria, was successfully completed in QIII 2009. This will be followed by a proof of concept trial in Phase II.

Further New Chemical Entities similar to tafoxiparin and sevuparin are being developed for other indications.